TelyRx Holdings Inc. (TELY.TO) is gaining attention as it prepares to present its growth story at an upcoming investor conference.
In the latest trading session, TelyRx Holdings Inc. saw a notable rise of 4.00%, closing at CA$2.60. This increase follows the company's announcement that it will showcase its recent achievements and future potential at the Global Technology Virtual Investor Conference.
Investor takeaway: TelyRx's upward movement reflects growing investor confidence as the company engages with the market and shares its growth trajectory.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$65.12M
52W high
$4.25
52W low
$2.00
1W change
+4.17%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 140.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.00
+140.0% Upside
Current Price
C$2.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
83.6%
Annualized
90-Day Vol
93.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.09
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.36 | C$1.77 โ C$3.14 |
| 60 trading days | C$2.22 | C$1.48 โ C$3.34 |
| 90 trading days | C$2.09 | C$1.27 โ C$3.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
TelyRx Holdings Inc. Rises 4.00% in One Day
The stock's recent performance shows increasing optimism among investors as the company prepares for an important presentation.
Bull case
TelyRx recently reached a significant milestone by filling one million prescriptions and achieving a 35% sequential revenue growth. This strong operational momentum could attract even more investor interest.
Bear case
However, despite the positive trends, TelyRx has a negative profit margin and lacks a P/E ratio, indicating some financial challenges that potential investors should keep in mind.
Company Highlights and Growth Prospects
TelyRx has recently celebrated filling one million prescriptions, demonstrating its operational capacity and market demand. With a 35% sequential revenue growth over the last quarter, the company is positioning itself as a key player in the digital pharmacy space. Investors will likely be eager to hear more about these developments during the upcoming conference.
Upcoming Investor Engagement
Scheduled for July 9th, TelyRx's presentation at the Global Technology Virtual Investor Conference will offer an interactive platform for investors to engage directly with company leadership. This event is expected to clarify the company's strategic direction and growth potential, making it a crucial moment for both current and prospective shareholders. For more details, visit the TelyRx stock page.
Advertisement
